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Background: Inflammation has a major role in disease lead to renal failure and diabetes mellitus, 
controlling inflammation in diabetic kidney receivers could decrease morbidity and mortality. 
Objectives: This study designed for evaluating the efficacy of  pioglitazone on C-reactive protein 
and lipid profile in diabetic kidney transplant receivers.
Patients and Methods: In this double blinded clinical trial, 58 diabetic renal transplant receivers, 
in first month after transplantation, randomized into two groups; receiving insulin and 
pioglitazone (15 mg tablet daily, group A); and insulin and placebo (group B). Blood pressure, 
weight, body mass index (BMI) and laboratory data compared in before and after 4-month 
treatment in two groups by SPSS.
Results: Fifty-eight patients with mean age of  44.15 ± 2 years included. There were no 
significant difference between groups in demographic data and other baseline measured 
variables (P > 0.05) .The mean weigh and BMI were slightly increased in group A and 
decreased in group B. The mean hs-CRP was decreased 4.82 mg/dL in group A and 1.93 
mg/dL in group B (P = 0.007). The mean total serum cholesterol was significantly decreased 
34 mg/dL in group A and 18.07 mg/dL in group B (P = 0.027). The mean serum HDL-C 
was significantly increased 13.31 mg/dL in group A and 5.89 mg/dl in group B (P < 0.001).
Conclusions: Pioglitazone seems to be a safe drug for reducing serum lipids and CRP in kidney 
transplant receivers with diabetes mellitus in short term. Long term effect of  this drug could 











Kidney transplantation is the most effective treatment 
for chronic renal failure. Patients with kidney 
transplantation are forced to use glucocorticoids in 
order to prevent rejection, which is the most basic 
element of  transplantation protocols (1). Treatment 
with glucocorticoids is associated with increased risk 
of  diabetes mellitus, insulin resistance, weight gain 
and blood pressure. Other factors such as hepatitis-C 
virus (HCV) or cytomegalovirus (CMV) infections 
can cause blood glucose disorder in patients with 
kidney transplantation. These cases can cause 
conflicts of  islets of  Langerhans cells. Asymptomatic 
CMV infection increases the risk of  diabetes after 
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renal transplantation (2,3). Diabetes is the most 
common cause of  chronic renal failure and in some 
cases; diabetes mellitus occurs immediately after 
transplantation. One of  the effects of  uncontrolled 
blood glucose is increasing inflammatory processes 
that have negative impacts on the prognosis of  renal 
transplantation (1-3). In conducted studies, using 
Thiazolidinedione has been emphasized to reduce 
adverse effects of  uncontrolled blood glucose that 
one of  these effects is reducing the inflammatory 
processes (4).
Controlling inflammatory processes in diabetic 
patients with kidney transplantation will have 
dramatic effects on reducing mortality, because the 
inflammatory processes are integral component of 
the diseases leading to renal failure and diabetes. Also, 
the experimental data showed that inflammation plays 
a role in atherogenesis process (5).
These drugs increase the sensitivity of  insulin 
receptors by PPAR-Ɣ receptors stimulation and 
reduce insulin resistance (6). Pioglitazone is a drug 
of  thiazolidinedione category that in addition to 
controlling glucose, reduces the inflammatory 
processes, and reduces the inflammatory processes. 
Based on studies, pioglitazone does not interfere with 
common transplant medications such as cyclosporine 
and mycophenolate mofetil. These drugs have been 
identified secure for damages to the connective tissue 
(4,5). Pioglitazone consumption is not contraindicated 
with mentioned medications and it does not cause 
any change in the creatinine or tacrolimus levels. 
Pioglitazone does not increase creatinine or the need 
for immunosuppressive drugs in patients with kidney 
transplantation (7-10).
2. Objectives 
This study designed to investigate the effects of 
pioglitazone on inflammatory processes in diabetic 
patients with kidney transplantation and if  this 
medicine would be effective, it will help to increase the 
quality of  life, duration of  life and kidney function, 
reduce health care costs related to transplantation, 
graft rejection, and the need of  alternative treatment 
in patients with kidney transplantation.
3. Patients and Methods 
3.1. Study patients
In this double blind randomized clinical trial, 
patients who had undergone kidney transplantation 
with diabetes, entered to the study. Fasting blood 
glucose (FBS) more than 126 mg/dl, from America 
diabetes association diagnostic criteria, was used to 
diagnose diabetes. The study protocol was designed 
in compliance with the principles of  the Helsinki 
Convention. Cigarette smokers or patients with heart 
failure FC II, III, hepatitis B and C, GFR less than 30 
cc/min, pregnancy, acute rejection with progressive 
renal impairment and creatinine more than 1 
mg/dl did not enter to the study. Patients gave written 
consent before entering the study. Patients divided 
randomly into two groups by closed label method. 
First group received insulin therapy with daily one 
15 mg pioglitazone tablet (A) for four months and 
second group received insulin therapy with placebo 
tablet (B). Placebo tablets were produced identical in 
shape and size with pioglitazone by its manufacturer 
and drug prescriber, those who visit the patients and 
filled the checklists in all stages as well as the person 
who performed the analysis were unaware of  drug 
compounds of  both groups. At the beginning of  the 
study, all patients were examined and interviewed, 
information about various diseases and history of 
present illness and consumed drugs were assessed 
through biography and present documents. On 
height, weight and waist circumference examinations, 
heart, lung and lower extremity examinations carried 
out for presence of  congestive heart failure and other 
mentioned diseases in the exclusion criteria (Figure 1). 
3.2. Laboratory assessments
Patients’ blood samples were taken to check for 
uric acid, lipid profile and hs-CRP. All patients were 
visited monthly, their blood glucose and creatinine 
were controlled monthly by experiments and if 
any problems or side effects were seen, patients 
were excluded from study. After four months the 
examinations were performed again.
Initial and four months laboratory tests were 
conducted using Pars Azmoon lab kits (TG91008, 
CHL91012, CRP92002, LDL-C92004, HDL-C92002, 
and Glu92008) at Labbafinejad hospital laboratory.
3.3. Ethical issues
(a) The research followed the tenets of  the Declaration 
of  Helsinki; (b) informed consent was obtained; and 
(c) the research was approved by the Urology and 
Nephrology Research Center and ethics committee 
of  Shahid-Beheshti University of  Medical Sciences 
and also has Iranian registry of  clinical trials code of 
IRCT2014050117413N2.
3.4. Statistical analysis
Data were analyzed by SPSS version 21 (SPSS Inc. 
Chicago, IL) for windows. At first, study patients 
described using mean descriptive statistics, standard 
deviation, and frequency then two groups compared 
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before intervention by independent sample t test and 
its nonparametric equivalent (Mann-Whitney) for 
quantitative variables, then Chi2 and Fisher exact tests 
used for qualitative variables. After treatment, groups 
wrer compared with above tests. Then before and 
after treatment amounts were compared in each group 
with paired sample t test, its nonparametric equivalent 
(Wilcoxon), and McNemar test. A, P amount less than 
0.05 considered as significant value.
4. Results 
A total of  58 patients were studied (29 patients in 
each group). Sixty-nine percent of  group A were male 
and 31% were female. This distribution was 62 males 
and 38% female in group B (P = 0.58).
The mean age was 44.15 ± 13.82 years that was 44.41 
± 14.24 years in group A and 43.68 ± 13.67 years 
in group B (P = 0.89). The mean weight was 78.73 ± 
11.39 kg and the mean BMI was 28.32 ± 3.76 kg/m2 
(Table 1).
The mean body weight was increased 2.09 ± 1.8 kg 
in group A and decreased 1.45 ± 2.21 kg in group B 
(P < 0.001). The mean waste circle size was decreased 
1.83 ± 4.01 cm in group A and 1.28 ± 3.82 cm in 
group B (P = 0.594). The mean fasting blood sugar was 
decreased 34.56 ± 15.97 mg/dL in group A and 23.83 
± 37.65 mg/dL in group B (P = 0.176). The mean uric 
acid was decreased 0.96 ± 0.73 in group A and 0.77 ± 
0.61 in group B (P = 0.317). The mean serum hs-CRP 
was decreased 4.82 ± 4.79 mg/dL in group A and 1.93 
± 2.56 mg/dL in group B (P = 0.007). In before-after 
evaluations (within groups), there were significant 
difference between before and after amounts in both 
groups (P < 0.05) (Figure 2).
4.1. Lipid profile
The mean triglyceride was decreased 48.59 ± 44.62 
mg/dL in group A and 33.52 ± 31.57 mg/dL in group 
B (P = 0.143). Mean cholesterol was also decreased 34 
± 27.78 mg/dL in group A and 18.08 ± 25.59 mg/
dL in group B (P = 0.027). The mean LDL-C was 
decreased 25.41 ± 20.37 mg/dL in group A and 18.34 
± 18.18 mg/dL in group B (P = 0.169). The mean 
HDL-C was increased 13.13 ± 7.48 mg/dL in group 
A and 5.89 ± 6.26 mg/dL in group B (P < 0.001) 
(Figure 3 and 4).
In before-after evaluations (within groups), there 
were significant difference between before and after 
lipid profile amounts in both groups (P < 0.05).
5. Discussion
According to results, 15 mg pioglitazone daily added 
to routine insulin therapy, could decrease serum hs-
CRP and cholesterol and increase serum HDL-C in 
diabetic renal transplant receivers. Pioglitazone could 
also help to control the blood glucose better.
Given that the patients enrolled to the study after renal 
transplantation and were treated with prednisolone 
and immunosuppressive drugs, it seems that these 
drugs have an impact on the amount of  lipid reduction 
in both groups.
The results of  this study are similar to the results of 
Figure 1. Study flow chart according to CONSORT 2010
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Luther et al in 2004 on serum lipids changes, however 
both studies did not report significant changes in 
lipids levels (7). 
The results of  the present study are inconsistent with 
Mattoo et al study in 2005, on significant reduction 
in levels of  LDL-C, cholesterol, triglycerides and hs-
CRP after treatment with pioglitazone. The difference 
is that, the target group of  Mattoo’s study was not 
patients with kidney transplantation and significant 
change has not been stated in the amount of  cholesterol 
and triglycerides in the control group. Follow-up 
period of  patients in Mattoo’s study was six months 
(8). The results of  the present study are consistent 
with the study of  Hanefeld et al too (9). Likewise, the 
results of  our study are similar to the study by Szapary 
et al on reduction levels of  inflammatory markers and 
serum lipids (11). Additionally, study of  Davidson 
et al on increase of  weight and BMI and decrease 
of  hs-CRP in pioglitazone group was in accord with 
the findings of  our study. However, the difference is 
that, Davidson et al study, was not on patients with 
kidney transplantation which follow-up period was 
24 weeks and also glimepiride drug prescribed for 
control group (12). Furthermore the findings of  Han 
Table 1. Comparison of  characteristics and laboratory findings before and after treatment between groups
Variables Pioglitazone (n=29) Placebo (n=29) P value
Age, year 44.41 (14.24) 43.36 (13.67) 0.89
Male, frequency (%) 20 (69.0%) 18 (62.1%) 0.58
Weight, kg
Before 78.58 (13.12) 77.87 (9.58) 0.923
After 80.67 (13.47) 77.43 (10.21) 0.306
Changes 2.09 (1.8) - 1.45 (2.21) <0.001
BMI, kg/m2
Before 28.2 (4.06) 28.42 (3.84) 0.826
After 28.95 (4.13) 27.88 (3.53) 0.294
Changes 0.74 (0.65) - 0.55 (0.84) <0.001
Waste, cm
Before 105.41 (13.25) 106.84 (10.26) 0.733
After 103.59 (12.28) 105.2 (10.96) 0.598
Changes - 1.83 (4.01) - 1.28 (3.82) 0.594
FBS, mg/dL
Before 137.43 (28.81) 141.65 (67.64) 0.762
After 103.33 (21.95) 117.82 (40.28) 0.104
Changes - 34.56 (15.97) - 23.83 (37.65) 0.176
Uric Acid, mg/dL
Before 5.83 (1.03) 5.62 (1.13) 0.499
After 4.87 (0.88) 4.86 (0.92) 0.951
Changes - 0.96 (0.73) - 0.77 (0.61) 0.317
hs-CRP, mg/dL
Before 8.38 (7.63) 9.06 (7.96) 0.743
After 3.56 (3.18) 7.13 (7.54) 0.026
Changes - 4.82 (4.79) - 1.93 (2.56) 0.007
TG, mg/dL
Before 207.34 (61.43) 196.82 (50.86) 0.481
After 158.76 (36.73) 163.31 (42.42) 0.664
Changes - 48.59 (44.62) - 33.52 (31.57) 0.143
Cholesterol, mg/dL
Before 189.07 (46.04) 183.68 (45.34) 0.656
After 155.07 (33.73) 165.62 (38.65) 0.273
Changes - 34.0 (27.78) - 18.07 (25.59) 0.027
LDL-C, mg/dL
Before 113.28 (25.54) 111.72 (29.76) 0.832
After 87.86 (11.38) 93.38 (17.89) 0.167
Changes - 25.41 (20.37) - 18.34 (18.18) 0.169
HDL-C, mg/dL
Before 48.89 (8.34) 50.62 (8.11) 0.428
After 62.21 (9.54) 56.52 (7.65) 0.015
Changes 13.31 (7.84) 5.89 (6.26) <0.001
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et al showed the changes in hs-CRP, and cholesterol 
in patients who taking pioglitazone, which was similar 
to our findings (13).
Likewise, the results of  the present study was 
consistent with Liu et al study in 2013 on reduction of 
hs-CRP levels. However, the difference is that, drug 
taking period was 24 weeks, the control group received 
sitagliptin drug and they concluded that pioglitazone 
had a significant effect in reducing plasma glucose, 
hs-CRP and HbA1c (14).
Additionally, present study approved the results 
of  the study by Suzuki et al., in 2013 on hs-CRP 
reduction. Importantly, blood pressure, HbA1c and 
fasting plasma glucose reduction are mentioned 
in their patients. The study stated positive effects 
of  medication with candesartan and pioglitazone 
on reducing blood pressure, inflammatory markers 
and improving metabolism in patients with type II 
diabetes (10).
Due to the significant reduction in serum lipids, 
Figure 3. Mean total cholesterol before and after 
intervention in two groups.
Figure 4. Comparison of  mean HDL-C changes after 
intervention between pioglitazone and placebo groupsFigure 2. Mean hs-CRP before and after intervention in 
two groups.
inflammatory markers, uric acid and fasting blood 
glucose of  patients with kidney transplantation 
after administration of  pioglitazone, this drug 
can prevent metabolic disorders after renal 
transplantation, however decision making about 
long-term effects of  drug on patients with kidney 
transplantation needs more studies (12-15). It is 
recommended that in future studies, longer treatment 
duration be considered for patients and patients 
are examined for longer duration. Also, the effect 
of  pioglitazone drug accompaniment with other 
anti-diabetic medications should be evaluated. The 
effect of  this drug on blood pressure and HbA1c 
after transplantation could also be examined in 
future studies. Therefore, it is also suggested that the 
effect of  this drug be compared with other drugs in 
diabetic and non-diabetic patients who received organ 
transplantation.
6. Conclusions
Oral pioglitazone seems to be a safe drug for reducing 
serum lipids and hs-CRP in kidney transplant receivers 
with diabetes mellitus in short-term evaluation. Long-
term effect of  pioglitazone therapy in diabetic kidney 
transplanted patients could be evaluated in future 
studies. 
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